Efficacy and safety of rituximab in relapsing and progressive multiple sclerosis: a hospital-based study

Autores de IIS La Fe

• Carmen Alcala Salmeron

  Autor

• Francisco Carlos Pérez Miralles

  Autor

• Sara María García Gil-Perotín

  Autor

• Isabel Boscá Blasco

  Autor

• Bonaventura Casanova Estruch

  Autor

Participantes ajenos a IIS La Fe

• Gascon, F
• Navarre, A
• Coret, F

Grupos

• Investigación en Neuroinmunología y Esclerosis Múltiple

Abstract

Rituximab is considered as a potential therapeutic option in relapsing-remitting (RRMS) and progressive forms (PMS) of multiple sclerosis (MS). To investigate the effectiveness and safety of rituximab in MS. Observational study of effectiveness (clinical and radiological) and safety of rituximab in RRMS and PMS. A total of 90 rituximab-treated patients were collected: 31 RRMS and 59 PMS All patients had an active disease despite standard treatment. The annualized relapse rate (ARR) the year before rituximab was 0.86, 53.3% of patients had gadolinium enhanced lesion, and mean Expanded Disability Status Scale (EDSS) had increased from 4.2 to 4.9. During treatment, the ARR was reduced an 88.4% (p < 0.001). A significant decrease of EDSS to 4.6 was observed (p = 0.01) after 1 year of treatment, which remained stable during the second year in both groups. There was no evidence of disease activity in 70% of total sample, 74.2% of RRMS, and 67% of the PMS patients. Infusion-related symptoms were the most prevalent side effect (18.8%) and most were mild. Three thrombotic events were detected. Rituximab could be an effective and safe treatment in aggressive RRMS. Some selected PMS patients could also benefit from this treatment.

Keywords

• Multiple sclerosis; Relapsing-remitting multiple sclerosis; Progressive multiple sclerosis; Treatment; Rituximab; Anti-CD20 monoclonal antibody